Plus, rivals Hasbro and Mattel join hands Inside.com Part of Network April 28, 2023 Presented by Eli Lilly has applied for FDA approval for Tirzepatide, which has been shown to help people with type 2 diabetes and obesity lose an average of 16% body weight. Lilly's 2023 profit forecasts have been upgraded due to solid sales of its diabetes drug Mounjaro, making it a potential rival to Novo Nordisk's obesity treatment Wegovy. More: Tirzepatide has already been approved by the FDA to treat type 2 diabetes and notched up almost $500M in sales. The medication, which reduces appetite and boosts energy expenditure, is given by injection once a week. According to analysts, peak sales of tirzepatide could approach $50B, making it the most successful medication ever. Pharmaceutical companies are working to create new obesity and diabetes drugs to meet the increas...
Comments
Post a Comment